Madrigal Pharmaceuticals, Inc. MDGL
421.72 USD -3.49 (-0.82%)
Nov 13, 2026, 12:45 PM EST
414.16 Day range 424.92
353.54 52-week range 615.00
- YTD
- -27.58%
- 1 year
- -18.10%
- Market cap
- 9.82B
- Revenue (ttm)
- 1.43B
- Profit margin
- -10.89%
- EPS (ttm)
- -5.85
- Shares out
- 23.23M
- Forward P/E
- 37.93
- YTD return
- -27.58%
- 1-year return
- -18.10%
- Volume
- 120.08K
- Avg volume
- 352.64K
- Open
- 424.92
- Previous close
- 425.21
- Day's range
- 414.16 – 424.92
- 52-week range
- 353.54 – 615.00
- Beta
- -1.00
- Analysts
- Strong Buy
- Price target
- 688.94 (+63.4%)
- Earnings date
- Feb 18, 2027
5D +43.71 (+11.23%)
Key statistics
- Enterprise value
- 9.45B
- PEG ratio
- 0.00
- Price / sales
- 6.92
- Price / book
- 15.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.10%
- Free cash flow
- -112.43M
- Total cash
- 960.97M
- Total debt
- 354.22M
- Return on equity
- -24.82%
- Short % of float
- 10.80%
- 50-day average
- 480.46
- 200-day average
- 496.69
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 688.94 +63.4% upside
Now 421.72
- Target (low)
- 479.00
- Target (mean)
- 688.94
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate 1.92.
Financials — quick view
MDGL Revenue — quarterly 431.27M
MDGL Net income — quarterly 55.44M
MDGL EPS — quarterly 1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | 1.43 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.86315 | 1.83 | +2.69 | +312.01% |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences 
Kaplan Fox & Kilsheimer LLP Announces an Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) for Possible Securities Law Violations 
Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations 
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 8.1% Share Drop 
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns 
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (MDGL) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation 
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns 
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.23% | 2,143,131 | 911.28M | Jun 29, 2026 |
| RTW Investments LP | 8.58% | 1,993,687 | 847.74M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.33% | 1,936,099 | 823.25M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.89% | 1,833,333 | 779.55M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.77% | 1,340,020 | 569.79M | Jun 29, 2026 |
| Blackrock Inc. | 5.17% | 1,200,770 | 510.58M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 584,997 | 248.75M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.42% | 563,117 | 239.44M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.82% | 423,142 | 179.92M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.46% | 338,602 | 143.98M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.16% | 270,288 | 114.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 103.62M | Jun 29, 2026 |